Drug combination screening as a translational approach toward an improved drug therapy for chordoma.

Susanne ScheiplMichelle BarnardBirgit LohbergerRichard ZettlIva BrcicBernadette Liegl-AtzwangerBeate RinnerClaudia MeindlEleonore Fröhlich

Published in: Cellular oncology (Dordrecht) (2021)

Our screen revealed promising combinations with EGFRis, such as the ALK/MET-inhibitor crizotinib, the HDAC-inhibitor panobinostat or the topoisomerase-II-inhibitor doxorubicin, which are part of standard chemotherapy regimens for various bone and soft-tissue sarcomas.

Keyphrases

soft tissue
advanced non small cell lung cancer
histone deacetylase
high throughput
emergency department
high grade
tyrosine kinase
drug induced
electronic health record